Degarelix
Degarelix 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Castration Levels of Testosterone、Metastatic Prostatic Adenocarcinoma、Stage IV Prostate Cancer AJCC v8、Stage IVA Prostate Cancer AJCC v8。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
22 项
全球在招研究
8 项
已进入 III/IV 期
9 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- SWOG Cancer Research Network
- Jose Pablo Leone
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- M.D. Anderson Cancer Center
- City of Hope Medical Center
- NYU Langone Health
- University College, London
- National Cancer Institute (NCI)
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Chile、Colombia、Mexico、瑞士、英国、芬兰、中国、比利时
正在招募患者的 Degarelix 研究
ETHAN - ET for Male BC
II 期招募中美国NCT05501704Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
III 期招募中美国ChileColombiaMexicoNCT03678025The COSMYC Trial (COmbined Suppression of MYC)
II 期招募中美国NCT06922318Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
II 期招募中美国NCT05873192Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
II 期招募中美国NCT04734730Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
II 期招募中美国NCT06059118Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
不适用招募中美国NCT07142967Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
III 期招募中英国NCT07751133NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
I 期 / II 期招募中美国NCT06066437ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
II 期招募中美国NCT06397703A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
I 期 / II 期招募中美国NCT04633252Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
II 期招募中美国NCT07142551Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
III 期招募中美国NCT04423211Cardiometabolic Consequences of the Loss of Ovarian Function
IV 期招募中美国NCT06264882Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
II 期招募中美国NCT07801664Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
II 期招募中美国NCT07455903Prostate Medication, Metabolism and Gut Microbiota
IV 期招募中芬兰NCT06001619Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
III 期招募中中国NCT07477626Bioenergetic Effects of Aging and Menopause (BEAM)
IV 期招募中美国NCT04043520Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
II 期招募中美国NCT07313241Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
II 期 / III 期招募中比利时NCT06282588Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
II 期招募中美国NCT06378866
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。